Primary hyperparathyroidism is associated with a higher level of serum uric acid: A systematic review and meta-analysis.
hyperuricemia
meta-analysis
parathyroid hormone
primary hyperparathyroidism
uric acid
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
30
08
2019
revised:
10
10
2019
accepted:
10
10
2019
pubmed:
7
11
2019
medline:
17
12
2020
entrez:
7
11
2019
Statut:
ppublish
Résumé
Studies have suggested that primary hyperparathyroidism could be a risk factor for hyperuricemia although the results were not consistent across the studies. This systematic review and meta-analysis was performed in order to identify all available studies and summarize their results together. A systematic review was performed using EMBASE and MEDLINE from inception to August 2018 to identify all cohort studies that consisted of 2 cohorts, a cohort of patients with primary hyperparathyroidism and a cohort of individuals without hyperparathyroidism. Eligible studies had to provide data on mean serum uric acid level and standard deviation of both cohorts, which would be extracted to calculate mean difference (MD). Pooled MD was then calculated by combining MDs of each study using a random-effects model. Funnel plot was used for evaluation for publication bias. A total of 9 cohort studies met the inclusion criteria and were included into the meta-analysis. The pooled analysis found that patients with primary hyperparathyroidism had a significantly higher level of serum uric acid than individuals without hyperparathyroidism with the pooled MD of 65.00 μmol/L (95% CI 37.74-92.25). The statistical heterogeneity was high with I Patients with primary hyperparathyroidism had a significantly higher level of serum uric acid compared to individuals without hyperparathyroidism.
Identifiants
pubmed: 31692271
doi: 10.1111/1756-185X.13740
doi:
Substances chimiques
Biomarkers
0
Uric Acid
268B43MJ25
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
174-180Informations de copyright
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Munoz-Torres M, Garcia-Martin A. Primary hyperparathyroidism. Med Clin. 2018;150(6):226-232.
Corbetta S, Mantovani G, Spada A. Metabolic syndrome in parathyroid diseases. Front Horm Res. 2018;49:67-84.
Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease-a review. Eur Heart J. 2004;25(20):1776-1787.
El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: a review. J Adv Res. 2017;8(5):487-493.
Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim Acta. 2018;484:150-163.
Kanbay M, Jensen T, Solak Y, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player. Eur J Intern Med. 2016;29:3-8.
Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15 Suppl):S435-S442.
Bergenfelz A, Bladstrom A, Their M, Nordenstrom E, Valdemarsson S, Westerdahl J. Serum levels of uric acid and diabetes mellitus influence survival after surgery for primary hyperparathyroidism: a prospective cohort study. World J Surg. 2007;31(7):1393-1400; discussion 401-2.
Ljunghall S, Akerstrom G. Urate metabolism in primary hyperparathyroidism. Urol Int. 1982;37(2):73-78.
Valdemarsson S, Lindblom P, Bergenfelz A. Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Intern Med. 1998;244(3):241-249.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-605.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557-560.
Broulik PD, Stepan JJ, Pacovsky V. Primary hyperparathyroidism and hyperuricaemia are associated but not correlated with indicators of bone turnover. Clin Chim Acta. 1987;170(2-3):195-200.
Yamamoto S, Hiraishi K, Nakamura S, Ghazizadeh M. Serum and urinary uric acid in primary hyperparathyroidism. Br J Urol. 1987;59(5):386-389.
Pepersack T, Jabbour N, Fuss M, Karmali R, Van Geertruyden J, Corvilain J. Hyperuricemia and renal handling of urate in primary hyperparathyroidism. Nephron. 1989;53(4):349-352.
Lind L, Ljunghall S. Serum urate and renal function in different forms of hypercalcemia. Exp Clin Endocrinol. 1992;99(2):87-90.
Delfini E, Petramala L, Caliumi C, et al. Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism. 2007;56(1):30-36.
Erem C, Kocak M, Hacihasanoglu A, Yilmaz M, Saglam F, Ersoz HO. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels. Exp Clin Endocrinol Diabetes. 2008;116(10):619-624.
Broulik PD, Broulikova A, Adamek S, et al. Improvement of hypertension after parathyroidectomy of patients suffering from primary hyperparathyroidism. Int J Endocrinol. 2011;2011:309068.
Ishay A, Herer P, Luboshitzky R. Effects of successful parathyroidectomy on metabolic cardiovascular risk factors in patients with severe primary hyperparathyroidism. Endocrine Practice. 2011;17(4):584-590.
Kahal H, Aye M, Rigby AS, Sathyapalan T, England RJA, Atkin SL. The effect of parathyroidectomy on neuropsychological symptoms and biochemical parameters in patients with asymptomatic primary hyperparathyroidism. Clin Endocrinol. 2012;76(2):196-200.
Sugimoto R, Watanabe H, Ikegami K, et al. Down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 2017;91(3):658-670.
Weinman EJ, Eknoyan G, Suki WN. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest. 1975;55(2):283-291.
Carroll R, Matfin G. Endocrine and metabolic emergencies: hypercalcaemia. Ther Adv Endocrinol Metab. 2010;1(5):225-234.